Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3

Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3

Albinterferon alfa-2b (albIFN) is a fusion protein of recombinant human albumin/recombinant interferon (IFN)-α-2b, with â200-h half-life. Safety/efficacy of albIFN q4wk was evaluated in 391 treatment-naive patients with chronic hepatitis C virus (HCV) genotype 2/3. Patients were randomized 3:4:4:4 t...

Full description

Saved in:
Bibliographic Details
Main Authors: S. Pianko, S. Zeuzem, W. L. Chuang, G. R. Foster, S. K. Sarin, R. Flisiak, C. M. Lee, P. Andreone, T. Piratvisuth, S. Shah, A. Sood, J. George, M. Gould, P. Komolmit, S. Thongsawat, T. Tanwandee, J. Rasenack, Y. Li, M. Pang, Y. Yin, G. Feutren, I. M. Jacobson
Format: Journal
Published: 2018
Subjects:
Immunology and Microbiology
Medicine
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84864665171&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/51724
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University

Internet

https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84864665171&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/51724

Similar Items